PRMT5 and colorectal carcinoma: Following this line, the joined inhibition of MTAP and MAT2A promotes lethality in tumor models of CRC by reducing SAMe availability and increasing MTA level, thus rising MTA/SAMe ratio and inhibiting PRMT5 activity [259].